Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.
1. A composition comprising uniform, rigid, spherical nanoporous calcium phosphate particles, wherein 50% or more of the particles have an average particle diameter of 2 microns or less as measured by scanning electron microscopy, and wherein the particles are complexed with an active agent.
2. The composition according to claim 1 , wherein the particles have a porosity ranging from 30% to 85% as determined by the standard ASTM D4284-88 test method.
3. The composition according to claim 2 , wherein the particles have an internal surface area ranging from 10 m 2 /g to 150 m 2 /g as determined by the standard ASTM D3663-03 test method.
4. The composition according to claim 1 , wherein the particles are produced by:
preparing a fluid composition of calcium phosphate crystals;
spray drying the fluid composition to produce precursor particles; and
subjecting the precursor particles to an elevated temperature ranging from 300 to 800° C. for a period of time ranging from 1 hour to 10 hours to produce uniform, rigid, spherical nanoporous calcium phosphate particles.
5. The composition according to claim 1 , wherein the composition is a topical formulation.
6. The composition according to claim 1 , wherein the amount of active agent complexed with the particles ranges from 0.01 mg to 300 mg of active agent per gram of particles.
7. A method of delivering an active agent to a subject, the method comprising:
applying a composition comprising:
uniform, rigid, spherical nanoporous calcium phosphate particles, wherein 50% or more of the particles have an average particle diameter of 2 microns or less as measured by scanning electron microscopy, and wherein the particles are complexed with an active agent;
to a topical region of the subject to deliver the active agent to the subject.
8. The method according to claim 7 , wherein the particles have a porosity ranging from 30% to 85% as determined by the standard ASTM D4284-88 test method.
9. The method according to claim 8 , wherein the particles have an internal surface area ranging from 10 m 2 /g to 150 m 2 /g as determined by the standard ASTM D3663-03 test method.
10. The method according to claim 7 , wherein the amount of active agent complexed with the particles ranges from 0.01 mg to 300 mg of active agent per gram of particles.
11. The method according to claim 7 , wherein the topical region is a mucosal location.
12. The method according to claim 7 , wherein the topical region is a keratinized skin surface.
13. The method according to claim 12 , wherein the method comprises delivering the active agent at least into the stratum corneum of the subject.
14. The method according to claim 12 , wherein the method comprises delivering the active agent into the deep stratum corneum of the subject.
15. The method according to claim 12 , wherein the method comprises delivering the active agent through the stratum corneum.
16. The method according to claim 12 , wherein the method comprises delivering the active agent into the dermis of the subject.
17. The method according to claim 12 , wherein the method comprises systemically delivering the active agent to the subject.
18. The composition according to claim 1 , wherein more than 50% of the particles have an average particle diameter ranging from 0.1 μm to 2 μm.
19. The method according to claim 7 , wherein more than 50% the particles have an average particle diameter ranging from 0.1 μm to 2 μm.